This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jeffrey M. Karp, MD; Michael S. Perkel, MD; Theodore Hersh, MD; Alexander S. McKinney, MD

JAMA. 1981;246(17):1934-1935.

Abstract
Five patients with tardive dyskinesia (average age, 64 years) were treated with a central dopamine blocking agent, metoclopramide hydrochloride. The duration of symptoms ranged from four to 30 months. A pretreatment disability score was graded (0 to 4) for buccolingual, extremity, and truncal movements and for duration of tongue protrusion. A 59% improvement was achieved in total disability scores. Tongue protrusion demonstrated the most noticeable improvement. The average daily dosage ranged from a minimum of 20 mg to a maximum of 80 mg given in divided doses. Duration of follow-up ranged from three to eight months. Preliminary data suggest that metoclopramide may be effective in the treatment of tardive dyskinesia.

(JAMA 1981;246:1934-1935)

Author Affiliations
From the Departments of Neurology (Drs Karp and McKinney) and Internal Medicine (Drs Perkel and Hersh), Emory University School of Medicine, Atlanta. Dr Karp is now with the Mease Clinic, Dunedin, Fla.

Footnotes
Reprint requests to Emory University Clinic, 1365 Clifton Rd NE, Atlanta, GA 30322 (Dr Perkel).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Metoclopramide-Induced Movement Disorders: Clinical Findings With a Review of the Literature
Miller and Jankovic
Arch Intern Med 1989;149:2486-2492.
ABSTRACT